Seeking Alpha

Smith On Stocks'  Instablog

Smith On Stocks
Send Message
Follow @SmithOnStocks on Twitter for more updates (http://twitter.com/#SmithOnStocks Please read this section carefully for some important disclosures. Who Am I? My name is Larry Smith. My career was spent on Wall Street as a biotechnology and pharmaceuticals analyst and also as Director of... More
My company:
SmithOnStocks.com
My blog:
Smith On Stocks
  • Northwest Biotherapeutics: The Investment Tide May Be Turning Positive  2 comments
    Jun 12, 2014 9:15 AM | about stocks: NWBO

    I have just written a new report that goes over recent news on the company in regard to DCVax Direct and DCVax-L and then goes into the issues that have affected the stock this year and upcoming events that will determine the stock price in the balance of the year. NWBO may have turned a corner and gained the high ground against an intense shorting program directed at the stock. I continue with my buy on the stock. This report is free for all interested investors.

    Since the beginning of the year, Northwest Biotherapeutics (NASDAQ:NWBO) has been the subject of significant shorting activity. The battle of the shorts against the longs can be seen by looking at the rise in stock sold short that is provided by NASDAQ and the price action. On December 31, 2013 there were 3.4 million shares that were short and the price closed at $3.77. By February 28, 2014 the short interest was 4.6 million and the price closed at $7.09. By May 30, 2014 the short interest 6.7 million and the stock closed at $5.98. The closing price yesterday, June 11, was $6.41.

    The shorts seem to have had a significant impact on the stock since March. The stock price is flat despite the very positive announcement of the approval of DCVax-L in Germany for the treatment of all gliomas (brain tumor) under the German hospital exemption early access program. This approval for five years goes far beyond the disease target for the phase 3 trial that is glioblastoma multiforme, the most aggressive form of brain cancer. DCVax-L is also eligible for reimbursement in Germany comparable to drugs that have gone through the traditional approval process. This was the first such approval for any systemic drug under this program since it was implemented in 2011. This is a really big deal. In addition to the German approval of DCVax-L, NWBO has released some very interesting early data on DCVax Direct that is also exciting.

    Disclosure: The author is long NWBO.

    Stocks: NWBO
Back To Smith On Stocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • bwitcher
    , contributor
    Comments (12) | Send Message
     
    Hey Larry,

     

    One question that has been bugging me: When I read the report showing how these test were being administered, I saw that the 2 groups were 1) getting NWBO treatment withe standard care and 2) placebo with standard care.

     

    What does standard care include? I saw that one of the patients said they were sick, but it was believed it was to due to another medication.

     

    Are these patients receiving any other treatments for cancer? or are they just getting standard care like pain relief? I'm just wondering if NWBO treatment is being used in conjunction with others or are the tests relying on NWBO solution to address the cancer alone?

     

    Thanks.
    13 Jun, 01:42 PM Reply Like
  • Smith On Stocks
    , contributor
    Comments (870) | Send Message
     
    Author’s reply » I suggest that you follow the link in this report to a much more in-depth report on my website. This report is free on my website. It should answer your questions.
    13 Jun, 01:50 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.